Theralase Releases 2019 Annual General Meeting Video Presentations
Toronto, Ontario – June 28, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTCQB), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to release the video presentations of this year’s Annual General Meeting (“AGM”).
The AGM was held at Theralase’s corporate office in Toronto, Ontario on June 27, 2019 and is available at https://youtu.be/Y_gWz2XvhuU
The pre-recorded videos feature Dr. Girish Kulkarni, Assistant Professor with the Department of Surgery, Faculty of Medicine at the University of Toronto, Uro-Oncologist and Principal Investigator (“PI”), University Health Network (“UHN”) discussing the successful completion of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“ACT-NMIBC”) and Dr. Michael Jewett, Professor of Surgery (Urology) at the University of Toronto and Uro-oncologist at Princess Margaret Cancer Centre, UHN discussing the ACT-NMIBC clinical study design.
Shawn Shirazi, Ph.D., CEO – Drug Division, Theralase stated that, “The Company is pleased to work with Dr. Jewett and Dr. Kulkarni, with their vast expertise in the field of uro-oncology on this clinical study. Their experience and guidance have been indispensable in assisting Theralase to launch the Phase II ACT-NMIBC study. The successfully completed Phase Ib NMIBC clinical study demonstrated Complete Response (“CR”) in two patients treated at the therapeutic dose (0.70 mg/cm2) at 360 days post initial single treatment. The Company has been extremely pleased with the performance of our patented study drug (TLD-1433) and study device (TLC-3200) in the Phase Ib NMIBC clinical study and believe we are able to achieve comparable results in a Phase II NMIBC clinical study.”
Kipton Lade, B.Sc., M.Sc. MBA, CEO – Device Division, Theralase stated that, “It is remarkable what the Company has been able to accomplish, with the assistance of Dr. Jewett and Dr. Kulkarni. Now that the ACT-NMIBC clinical study has commenced, UHN is actively screening patients for enrollment, while Theralase is busy onboarding additional Canadian sites. In addition, Theralase has taken actions to increase the treatment safety and efficacy of the study device (TLC-3200), enabling the principal investigators the opportunity to perform safer and more effective study treatments. The phase II ACT-NMIBC clinical study will be pivotal in treating the hundreds of thousands of patients inflicted with this devastating disease and providing clinical evidence to the medical community of what our anti-cancer technology is capable of accomplishing.”
About Theralase® Technologies Inc.
Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.
This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company’s proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information: